Drug Approval | March 13, 2026
Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
Subscribe To Our Newsletter & Stay Updated
